Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
NCT04418999
Completed
Drug delivery platforms are an innovative exciting advancement in ophthalmology. They allow patients to eliminate topical medications which are generally associated with lack of compliance, difficulty of use and requiring help from family members. These delivery systems can be applied easily in office, and patients do not have to worry about drop insertion in their post-operative regimen. The results of this research project should help to answer the following question: Does the use of a physic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Illinois Eye Institute, Chicago, Illinois
Conditions: Keratoconus, Dry Eye, Allergy
Register for Updates
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
NCT05145400
Recruiting
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +2 locations
Conditions: Multiple Myeloma, Cancer
Register for Updates
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114
Recruiting
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back after previous cancer treatment, or the previous cancer treatment they had didn't work. The main aims of the study are: * to check the safety of PRL-02 depot given with and without... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Arizona Urology Specialists, Tucson, Arizona +23 locations
Conditions: Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Register for Updates
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
NCT01862315
Completed
The purpose of this study is to use both, liver pump treatment and systemic chemotherapy, to assess the effects this type of treatment has on the patient and the tumor. Liver pump treatment uses a metal pump that is surgically placed in the abdomen and gives chemotherapy directly to the liver. Systemic chemotherapy gives chemotherapy through a vein \[intravenously (IV)\] and treats the whole body. This type of treatment has been done before and had shown that people with both pump and systemic c... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/18/2025
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +5 locations
Conditions: Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma
Register for Updates
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
NCT02649790
Completed
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +45 locations
Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Register for Updates
TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery
NCT04393207
Terminated
The TAP block offers analgesia by blocking the sensory nerves of the anterior abdominal wall. The procedure is performed under ultrasound guidance, after identification of the external oblique, internal oblique and transverse abdominis muscle. Medication is injected in the neurofascial plane between the internal oblique and the tranversus abdominis muscle. Previous studies have demonstrated limited (\<24 hour) effect of the block when compared to the use of intrathecal morphine (considered to b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/18/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Opioid Use, Pain, Acute
Register for Updates
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467
Recruiting
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Nebraska Methodist Hospital ( Site 0053), Omaha, Nebraska +2 locations
Conditions: Ovarian Cancer
Register for Updates
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT04570631
Active Not Recruiting
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to determine recommended Phase 2 dose and change in disease symptoms of eftozanermin alfa in combination with bortezomib and dexamethasone to assess how efficient the treatment is in adult participants with relapsed/refractory... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Emory University, Winship Cancer Institute /ID# 222922, Atlanta, Georgia +18 locations
Conditions: Multiple Myeloma
Register for Updates
Radiosurgery Before Surgery for the Treatment of Brain Metastases
NCT04895592
Active Not Recruiting
This early phase I trial identifies the side effects of stereotactic radiosurgery before surgery in treating patients with cancer that has spread to the brain (brain metastases). Radiation may stimulate an anti-tumor immune response. Giving stereotactic radiosurgery before surgery may reduce the risk of the cancer coming back after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Register for Updates
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571
Recruiting
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Michigan Hematology and Oncology Consultants- Site Number : 8400036, Dearborn, Michigan +2 locations
Conditions: Plasma Cell Myeloma Refractory
Register for Updates
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147
Active Not Recruiting
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemother... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +226 locations
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Register for Updates
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04896658
Terminated
Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates